| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net sales | 11,369 | 11,142 | 10,358 | 10,635 |
| Cost of products sold, excluding amortization of intangible assets | 5,075 | 4,854 | 4,468 | 4,698 |
| Amortization of intangible assets | 420 | 420 | 420 | 470 |
| Research and development | 766 | 725 | 716 | 713 |
| Selling, general and administrative | 3,051 | 3,091 | 3,061 | 2,895 |
| Total operating cost and expenses | 9,312 | 9,090 | 8,665 | 8,776 |
| Operating earnings | 2,057 | 2,052 | 1,693 | 1,859 |
| Interest expense | 121 | 121 | 131 | 142 |
| Interest (income) | 77 | 71 | 82 | 91 |
| Net foreign exchange (gain) loss | 17 | 11 | 7 | 11 |
| Other (income) expense, net | 150 | 137 | 127 | 121 |
| Earnings before taxes | 2,180 | 2,150 | 1,778 | 1,940 |
| Taxes on earnings | 536 | 371 | 453 | 294 |
| Net earnings | 1,644 | 1,779 | 1,325 | 1,646 |
| Average number of common shares outstanding plus dilutive common stock options (in shares) | 1,749,361,000 | 1,750,835,000 | 1,747,220,000 | 1,747,597,000 |
| Average number of common shares outstanding used for basic earnings per common share (in shares) | 1,742,142,000 | 1,743,437,000 | 1,739,206,000 | 1,739,466,000 |
| Basic earnings per common share (in dollars per share) | 0.94 | 1.02 | 0.76 | 0.94 |
| Diluted earnings per common share (in dollars per share) | 0.94 | 1.01 | 0.76 | 0.94 |
ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT)